| Sep 24 |
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
|
| Sep 21 |
Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market
|
| Sep 20 |
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
|
| Sep 18 |
FDA expands Novartis’ Kisqali label to include early breast cancer patients
|
| Sep 18 |
Weight loss drug pricing under fire with pills on the horizon
|
| Sep 18 |
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
|
| Sep 18 |
Novartis’ Kisqali gets expanded FDA OK; Mene Pangalos joins Omega Funds
|
| Sep 17 |
Novartis Kisqali gains early breast cancer indication
|
| Sep 17 |
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
|
| Sep 17 |
Novartis' Kisqali Lowers Risk of Breast Cancer Recurrence by 28%
|
